stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Shares outstanding
Organon & Co.'s shares outstanding at the end of fiscal 2025 was $260.8M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $272.4M. Over the past ten years it has ranged from $253.0M (fiscal 2018) to $260.8M (fiscal 2025) — the current reading is the highest in ten years. Organon & Co. ranks 15th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $260.8M | 0.62% |
| FY2024 | $259.2M | 1.12% |
| FY2023 | $256.3M | 0.43% |
| FY2022 | $255.2M | 0.38% |
| FY2021 | $254.2M | 0.27% |
| FY2020 | $253.5M | 0.00% |
| FY2019 | $253.5M | 0.20% |
| FY2018 | $253.0M | 0.00% |
| FY2017 | $253.0M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $272.4M | 0.72% |
| Jun 2026 | $270.4M | 2.87% |
| Mar 2026 | $262.9M | 0.82% |
| Dec 2025 | $260.8M | 0.04% |
| 23 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.8B |
| NVO Novo Nordisk A/S compare | $4.4B |
| SNY Sanofi compare | $2.4B |
| BMY Bristol Myers Squibb Company compare | $2.1B |
| GSK GSK PLC Sponsored ADR compare | $2.0B |
| GRFS Grifols, S.A. compare | $681.6M |
| OGN Organon & Co. | $272.4M |
| BIIB Biogen Inc. compare | $147.8M |
| AMRN Amarin Corporation PLC compare | $21.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement